テネシーにおけるクローン病の臨床試験
テネシー内の拠点で、クローン病に関する10件の研究が参加者を募集しています。
テネシー内の都市
公式研究テキスト（英語）
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Vanderbilt Inflammatory Bowel Disease Clinic ( Site 5049), Nashville
- Quality Medical Research ( Site 5114), Nashville
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/10/02更新 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastrointestinal Associates - Knoxville - Dowell Springs Boulevard /ID# 283861, Knoxville
- Gastro One - Memphis /ID# 283948, Memphis
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/10/02更新 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Tri-Cities Gastroenterology, Kingsport
被験者募集中第4相
18歳〜80歳 · 全性別 · 2026/09/30更新 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- GI associates of Northeast Tennessee /ID# 265567, Johnson City
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT06548542Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastroenterology Center Of The Midsouth, Cordova
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Tri-Cities Gastroenterology-Site Number: 8400076, Kingsport
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/09/23更新 · NCT07184931A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Gastrointestinal Associates of Northeast Tennessee, Johnson City
被験者募集中第2相
18歳〜85歳 · 全性別 · 2026/09/22更新 · NCT06226883A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Gastro One, Cordova
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07577843Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Vanderbilt University Medical Center, Nashville
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/04/27更新 · NCT06456593A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Cordova
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/03/12更新 · NCT07113522ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。